

Instructions and Guidelines on Submitting an Application for Registration to Conduct Research INSTRUCTION: Please tick in the applicant column as appropriate

1.	A completed application form.	Applicant	MRC
2.	CATEGORY: REGISTRATION FEES PAID		25-02-7
	A US \$500 for Individual Researcher / studies		
1	AE US \$1 000 for Fast Track Review (New Studies)		4-17- 17
1	E US \$200 for Exempted from Ethics Review (New Studies)		20.79
	11 03 3200 for PhD (Turnaround time: 4 - 6 weeks) 115 850 for MSc. (Turnaround time: 1 week)		10000
			35.00 E.S.
3.			
5.	Masters & BSc to submit 2 CLEARLY LABELED flat files copies of the following documents:		A No.
	a. Research proposal summary (maximum 4 pages)		project (
	b. Full research proposal		N. Carlotte
	c. Informed consent forms: English & Vernacular Versions. (Shona/ Ndebele/ appropriate language)		1233 Told
	d. Letter of support from supervisor		100
	e. University Research Ethics Committee /IRB approved		200
	e. Supplementary information as applicable.		SEA CO
	f Permission letter from hand of institutional and the state of the st		100
	f. Permission letter from head of institution where data is to be collected (For research in schools, a letter from ministry of Education is a requirement).		
4.	BP (PhD) studies to submit 4 CLEARLY LABELED flat files (1 original plus 3 copies) of the following document  a. Letter from academic supervisor confirming that the third labeled (1 original plus 3 copies) of the following document		Sec. of
	a. Letter from academic supervisor confirming that s/he has authorized submission of proposal to MRCZ	is:	ASSESSED OF THE PARTY OF THE PA
	b. Name, contact details and detailed curriculum vitae of academic supervisor(s)	200	1000
-			\$10 mg
	c. For candidates registered with foreign institutions, please provide name contact details and letter from proposed		COVE S
	rocal co-supervisor/adviser confirming willingness to supervise/advise		1000
+	d. Four Copies of the following documents (1 original plus 3 copies):-		200
-	Completed MRCZ application form	Ŋ2-	4027
1	2. Research proposal summary (maximum 4 pages)	-	All the Control of th
-	3. Informed consent forms (English and applicable local languages)		THE PARTY OF
	4. Specimen Storage and shipment consent form. (English and applicable local languages)		A. D. C.
1	5. Questionnaires & Any other data collection tools (English and applicable local languages)		CONTRACTOR OF
1	6. Full research proposal (hard copy and electronic version)	12	EXTAG
+			1787 TO 17
1	Drug brochure or supplementary information if applicable     CVs for the P.I and Co-Investigators		New York
+	e. University Research Ethics Committee /IRB approval		3256 84
+	f. Permission letter from head of institution where data is to be collected		STATE OF THE
	(For research in schools, a letter from ministry of Education is a requirement)		
5.	A, AE & E studies to submit 4 CLEARLY LABELED flat files (1 original plus 3 copies) of the following documen	1	
	a. Research proposal summary (maximum 4 pages)		4000000
	b. Full research proposal and an electronic version as well.	X	200
	c. Informed consent forms: English & Vernacular Versions (Appropriate vernacular language)		SEST
+	d. CVs for the P.I and Co-Investigators  CVs for the P.I and Co-Investigators	х	The Carlot
		x	
	c. Drug brochure or supplementary information if applicable.		
	f. Permission letter from head of institution where data is to be collected (For research in schools, a letter from		
	ministry of Education is a requirement).	1	35.00
	g. Proof of funding on Sponsor's Letterhead	X	SA SECTION
	stration fees should be paid into the MRCZ Account:	X	
	unt Name : Medical Research Council of Zimbabwe Name : CBZ	VI ENTRE PER	
Branc			
	Code : COBZZWHA		
	ch Sort Code : 6101		
	unt Number : 01120068040016	ALCOHOL: V	

Ver. 1.4

19/02/16

MRCZ FORM 101

Page 1



For Office Use Only	Date received/
MRCZ//	FC EXP XMPT

## A. DETAILS OF RESEARCH TEAM

1.	Name of Principal Investigator (P.I)	MR. S. GAVURE				
2.	Nationality of P.I	Zimbabwean				
3.	Existing Qualifications	BED in ENVIRONMENTAL SCIENCE				
4.	Academic Title	BIOLOGY TEAC	HER			
5.	Institution & Dept.	KRISTE MAMBO	HIGH SCHOOL			
6.	Postal address	PRIVATE BAG 8	PRIVATE BAG 8095 RUSAPE			
7.	E-mail address	admin@kristeman	admin@kristemambo.co.zw			
8.	Telephone No.	0775 253 117\ 0712 768 828				
9.	Is this research expected to lead to the award of a higher degree for the PI or any other research team member? (Yes/No)	No				
	Degree Type	Undergraduate (BSc, BA,etc)	MSc/MA/MMed/ MPhil	PhD/DPhil	Other	
11.	Name of students if not the Pl	N/A				
12.	University/Institution where student is registered	KRISTE MAMBO	O HIGH SCHOOL	747 21		
13.	Students # and Year of Study	Name	Surname	Class	Sex	
		IRENE	TAKUNDWA	Upper 6	F	
		HAZEL	MUJATI	Upper 6	F	
		MAZVITA	WUTA	Upper 6	F	
		NYASHA	CHIHAMBIRO	Upper 6	F	
		MERCY	MUTEMA	Upper 6	F	
		MITCHELL	CHAUKURA	Upper 6	F	
		TINEVIMBO	CHIFEMA	Form 4	F	
		ENGELENE	BAYAI	Form 4	F	
		CHRISTABEL	NYAMBODZA	Form 4	F	
		NYASHA	JIM	Form 4	F	

Ver. 1.4 19/02/16 MRCZ FORM 101 Page 2



Co-investigators Names	Qualifications	Institution/Department
14. Ms. T. Machaka	Teacher	Kriste Mambo High School
15. Dr Rosyln Thelingwani	Chemist (PhD)	African Institute of Biomedical Science
		and Technology, Zimbabwe
16. Prof. Collen Masimirembwa	PhD	African Institute of Biomedical Science
		and Technology, Zimbabwe
17. Dr. Karembo	Doctor/Dematelogist	Rusape General Hospital

#### (Add rows if required)

#### **Advisory Committee**

Name	Role	Contact
Mr. S. Gavure	Male Teacher	0775 253 117
Ms. T. Machaka	Female Teacher	0777 073 107
Fr. A. Makokowe O.Carm	Religious Leader	0772 391 112
Mr. T. Shayi	Male Parent	0774 222 474
Mrs Chifema	Female Parent	0719 225 412
MP ( Headlands Constituency)	Member of Parliament (ward 10)	0776 235 224\ 0718 218 357
Mr. C. Chingosho	No. 1	4
Headman T.Chiro	Sabhuku	O773 362 550
Mr. T. Jinjika	Councilor(ward 10)	0773 286 379
Mr J.P Mangundya	Businessman	02242703000

### B. DETAILS OF RESEARCH COORDINATOR

1. Name	Mr. S. Gavure
2. Postal Address	Kriste Mambo High School
3. E-mail Address	simomogav@gmail.com
4. Telephone Number	•
5. Mobile Number	0775 253 117\ 0712 768 828
6. Site where Coordinator is stationed	Kriste Mambo

#### C. DETAILS OF THE PROPOSED RESEARCH

1.	Title of proposed research	Effects of school water on the skin of students at Kriste Mambo
2.	Proposed starting date	1 April 2019
3.	Proposed ending date	31 March 2020
4.	Performance site(s) in Zimbabwe	Zimbabwe
5.	Performance sites (outside Zimbabwe)	N/A

Ver. 1.4 19/02/16 MRCZ FORM 101 Page 3

	1		
	M	(E	\
	6		MED
ſ	6.	Total r	number o
91.			

6. Total number of study personnel	22
7. Budget (state currency & amount)	5 000 RTGSS
8. Name and address of Funding agency:	African Institute of Biomedical Science and Technology
9. Status of funding :	a)Submitted for funding  b)Pending  c) Funded  x

## D. COLLABORATING INSTITUTIONS

	Institution	Contact / Focal Person (Name)	Telephone #	Email
1.	African Institute of Biomedical Sciences & Technology (AiBST)	Frank Muzenda	0783300868	fmuzee@gmail.com
2.	Rusape General Hospital	Dr Karembo	0773 707 147	rusapehospitalmedsup@ gmail.com
3.	Rusape water Quality Services	Mr .B. Gwamura	0776 078 373	bgwamura@gmail.com
4.				

(Add rows if required)

### E. POPULATION

### F. TYPE OF STUDY

Population: Proposed inclusion crite	ria	Type of study (check all that applies)	
(Check all that applies)			
Males	:	Survey	: 🗆 x
Females	:  \_X	Secondary data	: 🗆
Adolescents (12 - 17 years)	: 🗆 X	Observational Clinical Trials	: 🗆
Children (Under 12 years of age)	: 🗆	Clinical trial	: 🗆
Pregnant women	:□	Lab Based/Biomedical Research	: 🗆 x
Foetuses	: 🗆	Record review	: 🗆
Elderly (over 65 years)	: 🗆	Operations Research	: 🗆
Prisoners	: 🗆	Qualitative/Social/Behavioural	: 🗆 x
Cognitively impaired	: 🗆	Device Study	: 🗆
Hospital inpatients	: 🗆		
Sexual Minorities	: 🗆	Other (specify) :	
Sex Workers	: 🗆		

-	-		-
Var	1	1	

MRCZ FORM 101

Page 4



## G. DETERMINATION OF RISK (Check all that applies)

			YES	NO
Doe	Does the research involve any of the following			
	1.	Human exposure to ionizing radiation	H	$\Box_{x}$
	2.	Fetal tissue or abortus		TIV
	3.	Investigational new drug	-	1 H
	4.	Investigational new device	1-	HT.
	5.	Existing data available via public archives/sources		H <sub>Y</sub>
	6.	Existing data not available via public archives	-	11/2
	7.	Observation of public behaviour	-	\rac{1}{\chinn{1}{\rac{1}{\chinn{1}{\
	8.	Is the information going to be recorded in such a way that participants can be identified	-	<del>-                                      </del>
	9.	Does the research deal with sensitive aspects of the participants behaviour, sexual behavior, alcohol use		∐x
_		or illegal conduct such as drug use		Пх
	10	. Could the information recorded about the individual if it became known outside of the research, place the	الا	
		participants at risk of criminal prosecution or civil liability	<del> </del>	-
	11	. Could the information recorded about the individual if it became known outside of the research, damage		LIX
		the participant's financial standing, reputation and employability?		

NOTE: Study involves collecting cattle blood.

H. FOR OFFICIAL USE	ONLY			
Risk of proposed research				
A) Minimal risk	X		**************************************	
B) Greater than minimal risk				
C) High Risk				
in and of themselves than those ord	narily encountered in daily life the the risk of drawing a small amo	or during the perform unt of blood from a h	ated in the proposed research are not nance of routine physical, psychologica nealthy individual for research purpose	al

#### I. TRAINING

	Has the research team undergone training in the following as appropriate:			If No please give dates when this will be done
1.	Research Ethics /Human Subjects Protection			
2.	ICH-GCP			
3.	Good Clinical Laboratory Practices			
4.	Good Data Management Practices			-
5.	Other (Specify if the team has taken any other similar/equivalent training)			

er. 1.4	19/02	/16
er. 1.4	19/02	



## J. CONFLICT OF INTEREST

all the sit set				VESTIGATOR				
[Name garding	of teacher my applic	r]cation for et	Mr. S. o	Gavure roval to conduct this stu	idy have been decla	declare that all pone	otential conflict	s of interes
• ]	Having a f Being a co	financial an onsultant fo	d/or busing the sour	ited to reporting: ness interests in the source of funding nsor that may be affecte		enorted in the study		
		T	T a spor		d by the research is			
Yes		No	x					
unders	arising stand and ibility sho	accept that	all inforn any tran	nation pertaining to this sgression.	application is a tru	in place for managing the reflection of the proje the projection of the projection o	ct proposed an	
SIGNA	TURE	FPRINCI	PAL INV	ESTIGATOR&	favor.	DATE22/0.	3/19	
		- 1 port		AND DATA ANALYS		DATE22/0.	3/19	
	TATIST	S project be	NNING A	AND DATA ANALYS	I <u>S</u>	Yes	No	
K. <u>S</u>	Has thi	s project be	NNING A	AND DATA ANALYS  wed by a professional state.	IS ntistician? N/A			
K. <u>S</u>	TATIST  Has thi  If N  Explora  If answ	s project be	en review ustify belo on popula	AND DATA ANALYS  yed by a professional states  ow.  tion genetics	IS ntistician? N/A			
K. <u>S</u>	TATIST  Has thi  If N  Explora  If answ	s project be No, please ju ntory study of ered "yes" t	en review ustify belo on popula	AND DATA ANALYS  yed by a professional states  ow.  tion genetics	IS ntistician? N/A			

Ver. 1.4 19/02/16

MRCZ FORM 101



#### L. CONSENT PROCESS

1. Consent r	rocess (Check all that	upplies)				
Written:	$\square x$					
Verbal/Oral:						
2. Consent	Language (Check al	l that applies)				
English:		□ x				
Local Languages	(List them below)					
Š.						
Shona						
Shona						
	AL TRIALS					
L. CLINIC			Yes Yes	No No	N/A	x



3.	Which of the following will be used? N/A
	a) investigational drug(s)
	b) new therapeutic applications of MCAZ approved drug (s)
	c) new combination of any of the above
	d) medical device
	ay incural device
4.	Briefly describe how this drug or device is a part of the proposed investigation. N/A
5.	For each drug or device to be used, please provide the following information: N/A
Gene	ric Name Trade or Brand
Gene	Trade of Brand
	Name Manufacturer
6.	Please give the risks, hazards, known contraindications. N/A
7.	Please give reasons for choice of drug(s) for this study. Include pertinent animal clinical tests or appropriate citations. N/A
	Di con la la la constanti de l
8.	Please provide dose schedule, route of administration, and duration of therapy. N/A
0	. Please describe assessment of patient while receiving therapy including clinical observations and laboratory tests. N/A
9.	. Please describe assessment of patient withe receiving therapy including children observations and reservations



## RESEARCH PROPOSAL SUMMARY

It is the MRCZ requirement that the composition of the Institutional Review Board (IRB) include individuals with varied backgrounds and education. Investigators are therefore required to attach (5) copies of a (maximum 4 pages) Research Proposal Summary using the headings provided below in terminology that is understandable across disciplines.

## 1. RESEARCH QUESTION TO BE ADDRESSED BY THIS PROPOSAL

#### 2. RATIONALE FOR RESEARCH

- Describe briefly the background of the study, and state reasons for conducting it.
- State objectives of study.

#### 3. METHODS

- Study design and rationale for that design. Explain how the study will be performed.
- Population : Sample size, outline criteria for selection and exclusion of participants, gender, ethnic group, performance sites (provide justification for single gender or group). For larger sample sizes on greater than minimal risk studies, provide justification of the sample size.
- Participants' state of physical health. Indicate if healthy, ill, seriously ill or terminally ill.
- Does the study involve any special populations: Participants will include: minors, fetuses, pregnant women, prisoners, mentally retarded, mentally disabled, or none of the above.
- If participants are from one of the above special populations, explain the necessity for including them.
- Specify source of participating participants, e.g. hospitals, clinics, institutions, prisons, industry, unions, schools, general population, etc. NOTE: If you plan to advertise for patients, the ad must be submitted to the MRCZ for review and approval prior to its publication and or posting.
- List all research procedures and/or interventions involving human participants (when applicable) including tests to be conducted and the analysis of samples (where applicable including where the analysis is to be done - if outside the country, application for biospecimen shipment and Foreign Researcher registration should be made to Research Council of Zimbabwe through MRCZ, please justify including how the samples are to be shipped, forms obtainable from RCZ website).
- Distinguish procedures which are part of routine care from those that are part of the study
- Questionnaire/interview instrument (when applicable)
  - If the study includes either of these, a copy of the instrument is to be appended to this application. If the instrument is in development stages, provide an outline of the types of questions to be asked and the expected date of completion and submission to the MRCZ.
- Methods of intervention: Will any new drugs or biologic agents be administered to the participants, or will previously used agents be used in a new manner? If yes, please note that you are also required to file a separate application with the Medicines Control Authority of Zimbabwe (MCAZ) and may not conduct your study without the approval of both the MCAZ and the MRCZ. You are also required to complete the relevant part in this application titled "Studies involving the testing of drugs and medical devices".
- Methods for dealing with adverse events
- Methods for dealing with illegal, reportable activities (e.g child abuse)

#### RISKS / BENEFITS TO PARTICIPANTS

- Describe in detail any potential risks
  - physical,
  - psychological,
  - social, legal,
  - ethical (e.g. confidentiality), or other and assess the likelihood and seriousness of such risks (none, low, moderate, and high).
  - Include the incidence of complications if known. You may use a narrative description if more appropriate or a table with 3 columns (Potential adverse effects, seriousness and likelihood of complications (Incidence if known.)
- Describe procedures for protecting against or minimizing potential risks.
- If the activity involves women who could become pregnant and is potentially harmful to a fetus, describe steps that will be taken to prevent pregnancy or exclude pregnant women.
- Assess potential benefits to be gained by the individual participants and explain why the benefits outweigh the risks.

Ver. 1.4 19/02/16

MRCZ FORM 101

Page 9



Assess benefits which may accrue to society in general as a result of the planned work.

## COSTS, COMPENSATION AND REIMBURSEMENTS

Will participants receive any compensation, monetary or other? If monetary, how much? Will participants be asked to assume any out-of-pocket costs for participating in the research? If yes, what? Identify expenses such as additional transportation, laboratory tests, supplies, cost of study drug if it becomes commercially available, etc.

### CONFIDENTIALITY ASSURANCES

Describe any means by which the participant's personal privacy is to be protected and confidentiality of data maintained. Include information on the following:

- Any sensitive information that will be gathered.
- Plans for record keeping
- Location of the data
- Data security
- Person responsible and telephone number
- Who will have access to the data
- Plans for disposal of the data upon completion of the study

## CONFLICT OF INTEREST (real or apparent)

Other than the normal scholarly gains, are there any other gains you might receive from taking part in this study?

## COLLABORATIVE AGREEMENTS

Provide letters of approval from collaborating institutions' IRBs and from other local IRBs from other sites.

### INTENDED USE OF RESULTS

Include plans for dissemination and utilization of study results

#### OTHER INFORMATION:

Any other information.

MRCZ FORM 101 19/02/16 Page 10 Ver. 1.4



## FULL RESEARCH PROPOSAL

Attach 5 COPIES of the full research proposal. The full proposal should include the following: Title, objectives, background and literature review, methodology (to include research design, participants and methods, ethical considerations, timetables etc. references, budget etc. Investigators may submit the full proposal in the funding agency format as long as it covers the above headings.

Please also attach copies of **curriculum vitae** for the Principal Investigators and all Co-investigators. The CVs should include the following:

Name,

Postal address,

Employers name and address,

Qualifications,

Ongoing Research Activities and role or % time allocated for each

Past research experience (relevant) and

Published Papers (relevant)

Principal Investigators or co-investigators who would have already submitted their CVs during the current year are exempted from this requirement.

#### INFORMED CONSENT

- Any kind of contact with human participants requires a disclosure/consent process.
- Attach a copy of the consent form (template is provided on the website www.mrcz.org.zw).
- Indicate how ( written) informed consent will be obtained
- If participants are minors or mentally disabled, describe how and by whom permission will be granted.
- Where will the record of consent be stored? (Consent forms must be kept for three years after the completion of the investigation, unless otherwise stipulated by the MRCZ).

Ver. 1.4 19/02/16



## SIGNATURE ASSURANCE SHEET

## Principal Investigator's Assurance Statement:

I certify that the information given by me is correct to the best of my knowledge, I am familiar with and understand the Medical Research Council of Zimbabwe's policy concerning research involving human participants (CIOMS Guidelines or Helsinki Declaration) and I agree:

(Please	check	all	that	app	lies)
---------	-------	-----	------	-----	-------

1.	x to accept responsibility for the scientific and ethical conduct of this research study;
2.	x to obtain prior approval from the relevant IRB as well as the MRCZ before amending or altering the research protocol or implementing changes in the approved consent form;

 x to immediately report to the relevant IRB and the MRCZ any serious adverse reactions and/or unanticipated effects on participants which may occur as a result of this study;

4. x to complete and submit the Continuing annual Review Form annually (when due) as well as the Final/Study termination form at the end of the proposed study.

5. x to submit the final study report to the MRCZ using standard form (MRCZ Termination Form 105).

6. x to pay one percent levy to the MRCZ upon approval of my protocol (for study monitoring and general research participants protection requirements).

Signature	Bovere	Da	te	22/03/19
	[Name of teacher]			
Print name	Mr. S. Gavure			
Signature of	Co-investigator Machaka	D	ate	22/03/19
Digitature of	[Name of 2 <sup>nd</sup> teacher]			
Print Name	Ms. T. Machaka			

SUBMIT FOUR COPIES OF THE ENTIRE APPLICATION PROPOSAL TO THE MRCZ OFFICES (The entire application package includes the application form, research proposal summary (2-3 pages), full research proposal (even in funding agency format), consent form and other relevant documents).

\*\*\*\*\*

Ver. 1.4 19/02/16 MRCZ FORM 101 Page 12

# INSTITUTIONAL ETHICAL REVIEW BOARD REVIEW AND ENDORSEMENT REQUIRED

## Statement from the Institutional Ethics Review Board:

The MRCZ will only accept for review and approval research proposals that have been found both scientifically and ethically acceptable by an Institutional Ethics Review Board (IERB) recognised and operating in accordance with the Guidelines on Institutional Ethical Review Boards set by the MRCZ. In the case of institutions without IERBs, investigators are advised to seek advise from the MRCZ Office.

We the Institutional Ethics Review	Committee established by	
(Name of Institution conducting the research/in v	which the research is to be conducted)	
do certify that we have reviewed th	ne research proposal titled	
submitted	by	
Submitted	бу	
We attest to the scientific and ethical merit of this study and project and do hereby recommend the project and series are signatured.	oposal to the MRCZ for approval.	, conduct the
	Date	
Signature Ethics Committee representative Name (Please Print) Signature: Head of Ethics Committee (or other authorized signatory) Name (Please Print)		
Contact Tel. Number :		
E-mail address :		
OFFICIAL STAMP OF INSTITUTION		
*Institution includes Universities, Hospita	ls, Research Institutes or Companies.	
	Last Updated:	09 February 2016
	FORM 101	Page 13
Von 1.4 19/02/16 MRCZ F	OKW 101	

Ver. 1.4